Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

799 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Can monitoring of intrathoracic impedance reduce morbidity and mortality in patients with chronic heart failure? Rationale and design of the Diagnostic Outcome Trial in Heart Failure (DOT-HF).
Braunschweig F, Ford I, Conraads V, Cowie MR, Jondeau G, Kautzner J, Lunati M, Munoz Aguilera R, Man Yu C, Marijianowski M, Borggrefe M, van Veldhuisen DJ; DOT-HF steering committee and investigators. Braunschweig F, et al. Among authors: ford i. Eur J Heart Fail. 2008 Sep;10(9):907-16. doi: 10.1016/j.ejheart.2008.06.016. Epub 2008 Aug 19. Eur J Heart Fail. 2008. PMID: 18715826 Free article. Clinical Trial.
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL Investigators. Fox K, et al. Among authors: ford i. Eur Heart J. 2009 Oct;30(19):2337-45. doi: 10.1093/eurheartj/ehp358. Epub 2009 Aug 31. Eur Heart J. 2009. PMID: 19720635 Clinical Trial.
Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L. Swedberg K, et al. Among authors: ford i. Eur J Heart Fail. 2010 Jan;12(1):75-81. doi: 10.1093/eurjhf/hfp154. Epub 2009 Nov 5. Eur J Heart Fail. 2010. PMID: 19892778 Free article. Clinical Trial.
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Sattar N, et al. Among authors: ford i. Lancet. 2010 Feb 27;375(9716):735-42. doi: 10.1016/S0140-6736(09)61965-6. Epub 2010 Feb 16. Lancet. 2010. PMID: 20167359
Heart rate reduction in cardiovascular disease and therapy.
Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Böhm M. Reil JC, et al. Among authors: ford i. Clin Res Cardiol. 2011 Jan;100(1):11-9. doi: 10.1007/s00392-010-0207-x. Epub 2010 Sep 1. Clin Res Cardiol. 2011. PMID: 20809390 Review.
799 results